Application of aminothiazole derivative in preparation of medicine for treating neurodegenerative diseases

The aminothiazole derivative INNA1605 inhibits MyD88 signaling and regulates microglia, solves the paradoxical effect of neuroinflammatory in Alzheimer's disease, significantly reduces Aβ deposition and neurotoxicity, and provides a response to Alzheimer's disease and depression effective treatment options.

CN118976027APending Publication Date: 2024-11-19WUHAN YINGNUO PHARMACEUTICAL CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411246517.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-06
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

The existing technology lacks effective drugs for the treatment of Alzheimer's disease, especially intervention strategies for neuroinflammation have not been fully developed, and the activation of microglia has a paradoxical effect in the course of the disease, requiring dynamic attention to the timing and intensity of intervention.

Method used

The aminothiazole derivative INNA1605 is used to inhibit MyD88 signaling, reduce the expression of proinflammatory cytokines, regulate the initiation of microglia and train immunity, reduce Aβ protein deposition, reduce neurotoxic inflammatory response, and protect neurons.

Benefits of technology

INNA1605 significantly improves cognitive impairment in Alzheimer's disease model mice, reduces pathological Aβ deposition in the brain, reduces neurotoxicity, and has potential therapeutic effects on Alzheimer's disease and depression, providing a prevention, relief and An effective medicine for treating neurodegenerative diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118976027A_ABST
    Figure CN118976027A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of medicines, and particularly discloses application of an aminothiazole derivative in preparation of a product for preventing, relieving or treating neurodegenerative diseases. The invention uses a small molecule compound INNA1605 to treat neurodegenerative diseases. The compound can improve cognitive impairment of an Alzheimer's disease model mouse, reduce pathological A beta deposition in the brain, regulate microglial cell start and train immunity to down-regulate inflammatory response and reduce neurotoxicity, and has a protection effect on neurons. Through the effects, INNA1605 is expected to provide an effective medicine for relieving and treating neurodegenerative diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of biomedicine, and in particular to the application of an aminothiazole derivative in the preparation of a drug for treating neurodegenerative diseases. Background Art

[0002] Alzheimer's disease (AD) is a chronic neurodegenerative disease of the aging population. Currently, there is a lack of effective drugs for the treatment of AD. With the aging of the population, the global prevalence of dementia is expected to triple by 2050. Alzheimer's disease is the main cause of dementia and has rapidly become one of the most expensive, harmful and burdensome diseases of the 21st century. The main strategies for the development of drugs for the treatment of AD include anti-amyloid β protein, anti-tau protein and anti-inflammatory strategies. In recent years, the development of clinical drugs for the treatment of AD targeting neuroinflammation is no longer focused solely on Aβ and tau protein, but on a variety of innovative targets, among which neuroinflammation is one of the important development directions. Neuroinflammation is considered to be a major component of the pathology of Alzheimer's disease.

[0003] Microglial activation is an important part of the neuroinflammatory immune response in the human brain and a key factor associated with the development of AD. Literature shows that in the presence of activated microglia, Aβ enhances the spread of tau protein and promotes the progression of AD. On the other hand, early detection of microglial activation has the effect of clearing Aβ and protecting neurons. The effect of microglial activation on Aβ shows disease course specificity and has contradictory effects in the progression of AD, suggesting that the timing and intensity of drug intervention against neuroinflammation should be dynamically monitored.

[0004] Trained immunity is a characteristic of innate immune memory. Innate immune cells undergo long-term changes in their functions through metabolic and epigenetic reprogramming, resulting in excessive or insufficient immune responses to secondary stimulation, and this immune response is non-specific. Studies have found that regulating the immune memory of microglia can affect neuroinflammation and the clearance of Aβ in AD. Trained microglia can promote neuropathology in mouse AD models, suggesting that regulating the trained immunity of microglia is a new direction for the prevention and treatment of AD.

[0005] Literature has shown that in the case of congenital deficiency of MyD88, the suppression of the early immune response of microglia may prevent them from fully activating to fight and clear Aβ protein. However, acquired MyD88 deficiency inhibits the pro-inflammatory activation of microglia, reduces neurotoxic inflammatory response, and maintains the normal function of microglia, which subsequently reduces the Aβ load in the brain. Congenital deficiency and acquired deficiency of MyD88 have opposite effects on AD, indicating that MyD88 plays an important role in the progression of AD. It is speculated that in the early stage of Aβ formation in AD mice, activation of the MyD88 pathway promotes microglial activation, reduces Aβ deposition, and delays the course of AD. In the late stage, microglia are trained under Aβ stimulation, and the activated microglia of the MyD88 pathway produce excessive neuroinflammation, thereby aggravating AD neuropathology. The trained immunity of microglia may explain the contradiction between the effects caused by congenital deficiency and acquired deficiency of MyD88 in the course of AD. In summary, MyD88 can be used as an intervention target for AD.

[0006] The small molecule compound INNA1605 can specifically inhibit MyD88 signal transduction, effectively reduce the expression of pro-inflammatory cytokines, and reverse the inflammatory response. In previous studies, it has been shown that MyD88 inhibitors have a good inhibitory effect on acute excessive immune inflammatory response and reduce reperfusion injury after acute cerebral infarction. The therapeutic effect and mechanism of MyD88 inhibitors on AD caused by chronic neurotoxic inflammation need further study. There are currently no reports on the effectiveness of INNA1605 in the treatment of Alzheimer's disease. Summary of the invention

[0007] In order to solve the above problems, the present invention provides an application of an aminothiazole derivative in the preparation of a drug for treating neurodegenerative diseases, and further extends it to neurodegenerative diseases with similar mechanisms. The present invention firstly finds that aminothiazole derivatives have good therapeutic effects on Alzheimer's disease and depression, and provides a new application of aminothiazole derivatives.

[0008] To achieve the above purpose, the technical solution adopted by the present invention is as follows:

[0009] The present invention provides the use of aminothiazole derivatives in preparing products for preventing, alleviating or treating neurodegenerative diseases.

[0010] Preferably, the neurodegenerative disease is Alzheimer's disease or depression caused by the involvement of neurotoxic inflammation.

[0011] The present invention also provides the use of aminothiazole derivatives in preparing products with neuron protective activity.

[0012] The present invention also provides the use of aminothiazole derivatives in preparing products having the function of reducing Aβ protein deposition.

[0013] The present invention also provides the use of aminothiazole derivatives in preparing products for regulating microglial activation and training immunity.

[0014] The present invention also provides the use of aminothiazole derivatives as neuron activity protectors or Aβ protein deposition inhibitors or microglial cell activation and training immunomodulators in the preparation of products for preventing, alleviating or treating neurodegenerative diseases.

[0015] Preferably, the product is a functional food, a health product or a medicine.

[0016] Preferably, the medicine includes but is not limited to injection, oral solution, tablet, capsule.

[0017] Preferably, the aminothiazole derivative is 3-(4-(4-benzylpiperazine-1-yl)-N-(4-phenylthiazole-2-)propionamide, code-named INNA1605, and has the following structural formula:

[0018]

[0019] Compared with the prior art, the present invention has the following beneficial effects:

[0020] The present invention relates to the use of aminothiazole derivative INNA1605 to treat neurodegenerative diseases. The compound can improve cognitive impairment in Alzheimer's disease model mice, reduce pathological Aβ deposition in the brain, reduce inflammatory response by regulating microglia activation and training immunity, reduce neurotoxicity, and have a protective effect on neurons. Through these effects, INNA1605 is expected to provide an effective drug for preventing, alleviating and treating neurodegenerative diseases. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] Figure 1 Chronic INNA1605 intervention slightly improved cognitive function (Morris water maze); # p<0.05, ## p<0.01vs Control group);

[0022] Figure 2 Chronic INNA1605 intervention significantly reduced Aβ deposition in the brain of APP / PS1 mice; Representative immunohistochemical images of the whole brain (A), cortex (B), and hippocampus (C) of each group of mice at 9 months of age and the percentage of Aβ plaque area (D); ### p<0.001vs Control group; *p<0.05vs APP / PS1; control group; APP / PS1 and APP / PS1+INNA1605 groups);

[0023] Figure 3 Chronic INNA1605 intervention significantly inhibited the activation of brain microglia in APP / PS1 mice; Representative immunohistochemical images of the whole brain (A), cortex (B), and hippocampus (C) of each group of mice at 9 months of age and the area percentage of Iba-1-positive microglia (D); # p<0.05, ### p<0.001vs Control group; *p<0.05, **p<0.01vs APP / PS1 group; control group; APP / PS1 and APP / PS1+INNA1605 groups);

[0024] Figure 4 Chronic INNA1605 intervention can significantly reduce the inflammatory response in brain tissue; (A) mRNA expression levels of TNF-α, IL-6, IL-1β, COX2, iNOS and MYD88 in the cortex of 9-month-old mice; (B) mRNA expression levels of TNF-α, IL-6, IL-1β, COX2, iNOS and MYD88 in the hippocampus of 9-month-old mice; ( # p<0.05, ### p<0.001vsControl group; *p<0.05, **p<0.01, ***p<0.001vsAPP / PS1 group);

[0025] Figure 5 INNA1605 can inhibit Aβ-induced microglial activation and pro-inflammatory factor secretion; CCK8 kit was used to determine the effect of different concentrations of INNA1605 on microglial viability; after pretreatment with different concentrations of INNA1605, the mRNA expression levels of inflammatory factors such as IL-1β, TNF-α, IL-6 and COX2 in microglial cells stimulated by Aβ; ( ## p<0.01, ### p<0.001vsControl group; *p<0.05, **p<0.01vsAβ group);

[0026] Figure 6 INNA1605 dose-dependently reduces Aβ-induced neurotoxicity and significantly improves neuronal viability; (A) CCK8 kit was used to measure the effects of different concentrations of INNA1605 on neuronal viability; (B) Viability of neurons treated with different conditioned media; ( ### p<0.001vs Control-CM group; **p<0.01, ***p<0.001vs Aβ-CM group);

[0027] Figure 7INNA1605 inhibited Aβ-induced microglial immune training and reversed the pro-inflammatory epigenetic modification of microglia; (*p<0.05, **p<0.01vs Aβ group);

[0028] Figure 8 INNA1605 prevents pathological changes caused by depressive behavior and neurotoxic inflammation induced by the coronavirus spike protein (CSDS- / SARS-907COV-2Spike RBD). DETAILED DESCRIPTION

[0029] In order to better explain the present invention, the main contents of the present invention are further explained below in conjunction with specific embodiments, but the contents of the present invention are not limited to the following embodiments.

[0030] Example 1: The therapeutic effect of INNA1605 on Alzheimer's disease.

[0031] Preparation and grouping of Alzheimer's disease mouse model: Model establishment: APP / PS1 transgenic mice were purchased from Shanghai Slake Laboratory Animal Co., Ltd. The transgenic mice spontaneously developed Alzheimer's disease when they were bred to 8 to 9 months of age and no additional treatment was required.

[0032] The experiment was divided into 3 groups:

[0033] Control group: C57BL / 6 mice, given an equal dose of solvent (ddH2O);

[0034] Model group (APP / PS1 group): APP / PS1 transgenic mice were given an equal dose of solvent (ddH2O);

[0035] Medication group (APP / PS1+INNA1605 group): APP / PS1 transgenic mice were given INNA1605 (twice a day, 25 mg / Kg each time, once intraperitoneally and once orally).

[0036] When the mice were 9 months old, Morris water maze test was performed to evaluate the spatial learning and memory ability of APP / PS1 mice. After the behavioral test, after deep anesthesia, some mice were fully exposed to the heart and aorta by thoracotomy. A 20 ml syringe with an infusion needle was inserted from the apex of the heart into the aorta, the needle was fixed, the right atrium was cut open, and 30 ml of 4 ° C saline was perfused through the aorta until most of the blood flowed out. The hippocampus and cortex tissues were carefully and quickly separated and removed, and stored at -80 ° C for subsequent biochemical analysis. The remaining mice were first perfused with 30 ml of 4 ° C saline, and then perfused with 30 ml of pre-cooled 4% paraformaldehyde. The whole brain was removed and fixed with 4% paraformaldehyde for 48 h. After dehydration, transparency, paraffin embedding, and sectioning, immunohistochemical analysis was performed. Immunohistochemical staining was used to detect pathological Aβ deposition and microglial activation levels, and RT-PCR was used to detect the expression levels of TNF-α, IL-1β, IL-6, COX-2, iNOS, and MyD88.

[0037] like Figure 1 As shown in the results, the memory of APP / PS1 transgenic mice treated with INNA1605 was better than that of the model group mice, although it did not reach the memory level of normal mice (i.e., the control group). We also found through immunohistochemistry that Figure 2 As shown in the figure, the Aβ deposition in the whole brain, cortex, and hippocampus of APP / PS1 transgenic mice treated with INNA1605 was significantly less than that in the model group. Figure 3 As shown in Figure 2, the area of ​​Iba-1 positive microglia in the whole brain, cortex, and hippocampus of mice treated with NNA1605 was significantly reduced compared with that in the model group. Figure 4 As shown in the data, compared with the model group, the expression levels of inflammatory factors such as TNF-a, IL-6, COX-2, iNOS and MyD88 in the cerebral cortex and hippocampus of the drug group were significantly decreased, indicating that INNA1605 can be used as a new drug for the treatment of Alzheimer's disease both in terms of efficacy and mechanism.

[0038] Example 2: INNA1605 inhibits microglial immune training, thereby reducing neurotoxicity and having a protective effect on neurons.

[0039] In vitro experiments were conducted using microglial cell lines (BV-2) and neuronal cell lines (SH-SY5Y) to establish an Aβ stimulation model, which was divided into the Control group, Aβ group, Aβ+1μM INNA1605 group, Aβ+5μM INNA1605 group, Aβ+10μM INNA1605 group, and Aβ+20μM INNA1605 group. After 24 hours of Aβ stimulation, BV-2 cells were collected to extract mRNA to measure the expression levels of pro-inflammatory mediators such as IL-1β, TNF-α, IL-6, and COX2. Chromatin immunoprecipitation and RT-PCR experiments were used to detect the changes in epigenetic modifications of BV-2 cells. In addition, a portion of the supernatant was collected as a conditioned medium for culturing SH-SY5Y cells, and the viability of SH-SY5Y cells was detected using a CCK8 kit 24 hours later.

[0040] like Figures 5-6 As shown in the results, the experimental results showed that within the range of 30 μmol / L, INNA1605 had no significant cytotoxicity to BV-2 cells and SH-SY5Y cells. Compared with the Aβ group, the activation of BV-2 cells treated with INNA1605 was inhibited, and the expression levels of inflammatory factors such as IL-1β, TNF-a, IL-6, and COX2 decreased. INNA1605 reduced Aβ-induced neurotoxicity in a dose-dependent manner and significantly increased the viability of SH-SY5Y cells. In addition, Figure 7 As shown, INNA1605 inhibited Aβ-induced microglial immune training and reversed the pro-inflammatory epigenetic modifications of microglia.

[0041] Example 3: The aminothiazole derivative INNA1605 is used for preventing and treating depression.

[0042] 6-7 week old male C57BL / 6J mice and male CD-1 rats were selected to establish depression model, defeat-induced depression (CSDS) model: C57BL / 6J mice were attacked by different CD-1 rats for 10 minutes every day for 10 consecutive days. At night, the two types of mice were kept in the same cage separated by transparent glass with holes to maintain the stress of being attacked. The experimental results are shown in Figure 8 As shown, the results showed that INNA1605 (TJ-M2010-5) significantly improved the pathological changes caused by depressive behavior and neurotoxic inflammation in the brain.

[0043] According to the technical solution proposed by the present invention, there is evidence that the small molecule compound INNA1605 has a potential anti-Alzheimer's effect. This effect is to train the immune system by inhibiting microglia, thereby reducing neurotoxic inflammatory responses, reducing the accumulation of Aβ, and protecting neurons. This discovery reveals the potential mechanism of INNA1605 in the treatment of Alzheimer's disease, which will help promote its new application exploration in the market and the development of drugs for Alzheimer's disease. In addition, INNA1605 is used to prevent and treat depression, indicating the potential of INNA1605 in the treatment of neurodegenerative diseases.

[0044] Other parts not described belong to the prior art.

Claims

1. Application of aminothiazole derivatives in the preparation of products for preventing, alleviating or treating neurodegenerative diseases.

2. The use according to claim 1, characterized in that: The neurodegenerative disease is Alzheimer's disease or depression caused by the involvement of neurotoxic inflammation.

3. Application of aminothiazole derivatives in the preparation of products with neuroprotective activity.

4. Application of aminothiazole derivatives in the preparation of products with the function of reducing Aβ protein deposition.

5. Application of aminothiazole derivatives in the preparation of products for regulating microglia activation and immune training.

6. Use of aminothiazole derivatives as neuronal activity protectors or Aβ protein deposition inhibitors or microglial cell priming and training immunomodulators in the preparation of products for preventing, alleviating or treating neurodegenerative diseases.

7. The use according to claim 1 or 3 or 4 or 5 or 6, characterized in that: The product is a functional food, a health product or a medicine.

8. The use according to claim 7, characterized in that: The medicine includes but is not limited to injection, oral solution, tablet and capsule.

9. The use according to claim 1 or 3 or 4 or 5 or 6, characterized in that: The aminothiazole derivative is 3-(4-(4-benzylpiperazine-1-yl)-N-(4-phenylthiazole-2-)propionamide, code-named INNA1605, and has the following structural formula: